Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA
Status:
Completed
Trial end date:
2017-06-02
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomised, double-blind, parallel-group, safety and efficacy study
of empagliflozin as add-on to GLP-1 RA in Japanese patients with Type 2 Diabetes Mellitus
with insufficient glycaemic control